Lorenza Landi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lorenza Landi has a total of 546 co-authors. Here are the top co-authors by number of shared publications:
- Federico Cappuzzo
Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy
179 shared publications - Biagio Ricciuti
Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
146 shared publications - Mark Magdi Awad
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
145 shared publications - Joao Victor Alessi
Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
142 shared publications - Gabriele Minuti
Department of Medical Oncology 2, IRCCS “Regina Elena” National Cancer Institute, Rome, Italy
141 shared publications - Mihaela Aldea
Medical Oncology Department, Institut Gustave Roussy, Villejuif, France
117 shared publications
Latest Publications
- 12 November 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF7
Second- and Third-Line Outcomes after Selective RET Inhibitor Failure in RET Fusion-Positive Metastatic Lung Cancer: A Real-World Analysis from the RET-MAP Registry
Purpose: Selective RET inhibitors (SRI) are the first-line standard for RET fusion–positive non–small cell lung cancer, but no treatment is established after progression. Real-world outcomes are needed to inform trial design and contextualize single-arm studies in this rare population. Experimental Design: Using the international RET-MAP registry (52 centers), we evaluated second-line platinum–pemetrexed (Pt-Pem) with or without immunotherapy (IO) after first-line SRI progression and characterized third-line treatments after exposure to both regimens in any order. Results: Among 207 patients treated with first-line SRI, 81 (39%) discontinued because of progression; 65 (80%) received subsequent therapy, most commonly Pt-Pem with or without IO (n = 35, 54%). At 53 months’ median follow-up, the real-world objective response rate was 41% (12/29), median real-world progression-free survival (rwPFS) was 6.1 months [95% confidence interval (CI), 4.8–11.4], and median overall survival (OS) was 13.7 months (95% CI, 8.7–26.5). Outcomes were similar with chemotherapy alone (n = 12) versus chemoimmunotherapy (n = 23) for rwPFS [5.9 vs. 6.8 months; hazard ratio (HR), 1.05; P = 0.903] and OS (18.5 vs. 13.7 months; HR, 0.83; P = 0.674). Three patients had rwPFS beyond 24 months with chemoimmunotherapy, all after short first-line SRI exposure. Among 32 patients receiving third-line therapy, taxane with or without antiangiogenic therapy was the most common (n = 11), with no responses and a median rwPFS of 1.5 months (95% CI, 0.8–NR). Conclusions: Second-line Pt-Pem with or without IO achieved a median rwPFS of 6.1 months. Third-line outcomes were poor, highlighting the need for new treatment strategies.
- 12 November 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF7
Second- and Third-Line Outcomes after Selective RET Inhibitor Failure in RET Fusion-Positive Metastatic Lung Cancer: A Real-World Analysis from the RET-MAP Registry
Purpose: Selective RET inhibitors (SRI) are the first-line standard for RET fusion–positive non–small cell lung cancer, but no treatment is established after progression. Real-world outcomes are needed to inform trial design and contextualize single-arm studies in this rare population. Experimental Design: Using the international RET-MAP registry (52 centers), we evaluated second-line platinum–pemetrexed (Pt-Pem) with or without immunotherapy (IO) after first-line SRI progression and characterized third-line treatments after exposure to both regimens in any order. Results: Among 207 patients treated with first-line SRI, 81 (39%) discontinued because of progression; 65 (80%) received subsequent therapy, most commonly Pt-Pem with or without IO (n = 35, 54%). At 53 months’ median follow-up, the real-world objective response rate was 41% (12/29), median real-world progression-free survival (rwPFS) was 6.1 months [95% confidence interval (CI), 4.8–11.4], and median overall survival (OS) was 13.7 months (95% CI, 8.7–26.5). Outcomes were similar with chemotherapy alone (n = 12) versus chemoimmunotherapy (n = 23) for rwPFS [5.9 vs. 6.8 months; hazard ratio (HR), 1.05; P = 0.903] and OS (18.5 vs. 13.7 months; HR, 0.83; P = 0.674). Three patients had rwPFS beyond 24 months with chemoimmunotherapy, all after short first-line SRI exposure. Among 32 patients receiving third-line therapy, taxane with or without antiangiogenic therapy was the most common (n = 11), with no responses and a median rwPFS of 1.5 months (95% CI, 0.8–NR). Conclusions: Second-line Pt-Pem with or without IO achieved a median rwPFS of 6.1 months. Third-line outcomes were poor, highlighting the need for new treatment strategies.
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Data from Clinical Outcomes and Predictors of Response to PD-(L)1 Blockade in Patients with NSCLC without Actionable Genomic Alterations Who Never Used Tobacco
Purpose:Predictive biomarkers of response to immune checkpoint inhibitors (ICI) remain poorly defined in patients with non–small cell lung cancer (NSCLC) without a history of tobacco use and lacking actionable genomic alterations (AGA). We aimed to identify clinical and molecular predictors of response to ICI-based regimens in patients who have never smoked and lack AGAs. Experimental Design:We retrospectively analyzed patients with metastatic, AGA-negative NSCLC who never smoke treated with ICI-based regimens across multiple independent cohorts. Tumor-infiltrating lymphocyte (TIL) densities were quantified using a machine learning–based algorithm, and immune cell biomarkers were assessed with multiplexed immunofluorescence. Transcriptomic correlates of ICI response were analyzed in the Stand Up To Cancer cohort. Results:Among 741 patients with AGA-negative NSCLC and no history of tobacco use, the objective response rate (ORR) was 23.2%, median progression-free survival (mPFS) was 4.5 months, and median overall survival (mOS) was 16.8 months. PD-L1 ≥90% and tumor mutational burden (TMB) ≥90th percentile were independently and significantly associated with improved ORR, mPFS, and mOS (all P <0.01). PD-(L)1 + CTLA-4 combinations outperformed chemoimmunotherapy and PD-(L)1 monotherapy in terms of mPFS and mOS. Transcriptomic analysis revealed enrichment of innate and adaptive immune pathways in responders, including increased MHC class I/II antigen presentation and T-cell activity. High TIL density was also associated with superior ORR and PFS. Multiplexed immunophenotyping confirmed higher immune cell infiltration in patients who experienced durable clinical benefit. Conclusions:We demonstrated how combination therapies may improve ICI outcomes in patients with AGA-negative NSCLC and no history of tobacco exposure. Very high PD-L1, TMB, and immune-enriched phenotypes may guide treatment personalization.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Clinical Outcomes and Predictors of Response to PD-(L)1 Blockade in Patients with NSCLC without Actionable Genomic Alterations Who Never Used Tobacco
Purpose:Predictive biomarkers of response to immune checkpoint inhibitors (ICI) remain poorly defined in patients with non–small cell lung cancer (NSCLC) without a history of tobacco use and lacking actionable genomic alterations (AGA). We aimed to identify clinical and molecular predictors of response to ICI-based regimens in patients who have never smoked and lack AGAs. Experimental Design:We retrospectively analyzed patients with metastatic, AGA-negative NSCLC who never smoke treated with ICI-based regimens across multiple independent cohorts. Tumor-infiltrating lymphocyte (TIL) densities were quantified using a machine learning–based algorithm, and immune cell biomarkers were assessed with multiplexed immunofluorescence. Transcriptomic correlates of ICI response were analyzed in the Stand Up To Cancer cohort. Results:Among 741 patients with AGA-negative NSCLC and no history of tobacco use, the objective response rate (ORR) was 23.2%, median progression-free survival (mPFS) was 4.5 months, and median overall survival (mOS) was 16.8 months. PD-L1 ≥90% and tumor mutational burden (TMB) ≥90th percentile were independently and significantly associated with improved ORR, mPFS, and mOS (all P <0.01). PD-(L)1 + CTLA-4 combinations outperformed chemoimmunotherapy and PD-(L)1 monotherapy in terms of mPFS and mOS. Transcriptomic analysis revealed enrichment of innate and adaptive immune pathways in responders, including increased MHC class I/II antigen presentation and T-cell activity. High TIL density was also associated with superior ORR and PFS. Multiplexed immunophenotyping confirmed higher immune cell infiltration in patients who experienced durable clinical benefit. Conclusions:We demonstrated how combination therapies may improve ICI outcomes in patients with AGA-negative NSCLC and no history of tobacco exposure. Very high PD-L1, TMB, and immune-enriched phenotypes may guide treatment personalization.
- 14 July 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (18) , 4095-4104
Clinical Significance of EGFR Amplification in Patients with EGFR -Mutated Metastatic Non–Small Cell Lung Cancer Receiving First-line Osimertinib
Purpose: With rapidly expanding treatment options for patients with epidermal growth factor receptor (EGFR)–mutated non–small cell lung cancer (NSCLC), identifying biomarkers that may assist in treatment selection is critical. The impact of EGFR amplification (EGFRAMP) on outcomes to osimertinib is currently unknown. Experimental Design: Patients with metastatic EGFR-mutated NSCLC who received first-line osimertinib and had undergone baseline next-generation sequencing (NGS) that included assessment of EGFRAMP were included. EGFRAMP was defined as an EGFR copy number (CN) ≥6. Results: Among 473 patients, 81 (17.1%) had EGFRAMP. Compared with patients with non-amplified EGFR (EGFRNon-AMP; n = 392), they frequently had TP53 comutations (80% vs. 55.4%, P < 0.001) and brain (50.6% vs. 34.3%, P = 0.008), liver (25.9% vs. 13.5%, P = 0.009), and bone (65.4% vs. 51.3%, P = 0.028) metastases. When treated with osimertinib, patients with EGFRAMP achieved a similar objective response rate (88% vs. 83%, P = 0.23) but shorter median progression-free survival [PFS; 11.6 vs. 19 months, hazard ratio (HR), 1.77; P < 0.0001] and overall survival (OS; 34 vs. 40.1 months; HR, 1.40; P = 0.040). EGFRAMP was consistently associated with worse PFS regardless of TP53 comutations; however, EGFRAMP was associated with worse PFS and OS in patients with EGFR exon 19 deletion, but not in those with EGFR L858R. Within EGFRAMP cases, a higher EGFR CN and the amplification of the mutant allele, as opposed to wild-type amplification, correlated with inferior outcomes. Among patients reassessed with NGS after osimertinib resistance (n = 113), those with baseline EGFRAMP more frequently showed acquired MET alterations (29% vs. 12%, P = 0.04). Conclusions: EGFR AMP correlates with distinct characteristics and worse outcomes to osimertinib monotherapy among patients with EGFR-mutated NSCLC.
- 14 July 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (18) , 4095-4104
Clinical Significance of EGFR Amplification in Patients with EGFR -Mutated Metastatic Non–Small Cell Lung Cancer Receiving First-line Osimertinib
Purpose: With rapidly expanding treatment options for patients with epidermal growth factor receptor (EGFR)–mutated non–small cell lung cancer (NSCLC), identifying biomarkers that may assist in treatment selection is critical. The impact of EGFR amplification (EGFRAMP) on outcomes to osimertinib is currently unknown. Experimental Design: Patients with metastatic EGFR-mutated NSCLC who received first-line osimertinib and had undergone baseline next-generation sequencing (NGS) that included assessment of EGFRAMP were included. EGFRAMP was defined as an EGFR copy number (CN) ≥6. Results: Among 473 patients, 81 (17.1%) had EGFRAMP. Compared with patients with non-amplified EGFR (EGFRNon-AMP; n = 392), they frequently had TP53 comutations (80% vs. 55.4%, P < 0.001) and brain (50.6% vs. 34.3%, P = 0.008), liver (25.9% vs. 13.5%, P = 0.009), and bone (65.4% vs. 51.3%, P = 0.028) metastases. When treated with osimertinib, patients with EGFRAMP achieved a similar objective response rate (88% vs. 83%, P = 0.23) but shorter median progression-free survival [PFS; 11.6 vs. 19 months, hazard ratio (HR), 1.77; P < 0.0001] and overall survival (OS; 34 vs. 40.1 months; HR, 1.40; P = 0.040). EGFRAMP was consistently associated with worse PFS regardless of TP53 comutations; however, EGFRAMP was associated with worse PFS and OS in patients with EGFR exon 19 deletion, but not in those with EGFR L858R. Within EGFRAMP cases, a higher EGFR CN and the amplification of the mutant allele, as opposed to wild-type amplification, correlated with inferior outcomes. Among patients reassessed with NGS after osimertinib resistance (n = 113), those with baseline EGFRAMP more frequently showed acquired MET alterations (29% vs. 12%, P = 0.04). Conclusions: EGFR AMP correlates with distinct characteristics and worse outcomes to osimertinib monotherapy among patients with EGFR-mutated NSCLC.
- 23 June 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (16) , OF1-OF11
Clinical Outcomes and Predictors of Response to PD-(L)1 Blockade in Patients with NSCLC without Actionable Genomic Alterations Who Never Used Tobacco
Purpose: Predictive biomarkers of response to immune checkpoint inhibitors (ICI) remain poorly defined in patients with non–small cell lung cancer (NSCLC) without a history of tobacco use and lacking actionable genomic alterations (AGA). We aimed to identify clinical and molecular predictors of response to ICI-based regimens in patients who have never smoked and lack AGAs. Experimental Design: We retrospectively analyzed patients with metastatic, AGA-negative NSCLC who never smoke treated with ICI-based regimens across multiple independent cohorts. Tumor-infiltrating lymphocyte (TIL) densities were quantified using a machine learning–based algorithm, and immune cell biomarkers were assessed with multiplexed immunofluorescence. Transcriptomic correlates of ICI response were analyzed in the Stand Up To Cancer cohort. Results: Among 741 patients with AGA-negative NSCLC and no history of tobacco use, the objective response rate (ORR) was 23.2%, median progression-free survival (mPFS) was 4.5 months, and median overall survival (mOS) was 16.8 months. PD-L1 ≥90% and tumor mutational burden (TMB) ≥90th percentile were independently and significantly associated with improved ORR, mPFS, and mOS (all P <0.01). PD-(L)1 + CTLA-4 combinations outperformed chemoimmunotherapy and PD-(L)1 monotherapy in terms of mPFS and mOS. Transcriptomic analysis revealed enrichment of innate and adaptive immune pathways in responders, including increased MHC class I/II antigen presentation and T-cell activity. High TIL density was also associated with superior ORR and PFS. Multiplexed immunophenotyping confirmed higher immune cell infiltration in patients who experienced durable clinical benefit. Conclusions: We demonstrated how combination therapies may improve ICI outcomes in patients with AGA-negative NSCLC and no history of tobacco exposure. Very high PD-L1, TMB, and immune-enriched phenotypes may guide treatment personalization.
- 23 June 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (16) , OF1-OF11
Clinical Outcomes and Predictors of Response to PD-(L)1 Blockade in Patients with NSCLC without Actionable Genomic Alterations Who Never Used Tobacco
Purpose: Predictive biomarkers of response to immune checkpoint inhibitors (ICI) remain poorly defined in patients with non–small cell lung cancer (NSCLC) without a history of tobacco use and lacking actionable genomic alterations (AGA). We aimed to identify clinical and molecular predictors of response to ICI-based regimens in patients who have never smoked and lack AGAs. Experimental Design: We retrospectively analyzed patients with metastatic, AGA-negative NSCLC who never smoke treated with ICI-based regimens across multiple independent cohorts. Tumor-infiltrating lymphocyte (TIL) densities were quantified using a machine learning–based algorithm, and immune cell biomarkers were assessed with multiplexed immunofluorescence. Transcriptomic correlates of ICI response were analyzed in the Stand Up To Cancer cohort. Results: Among 741 patients with AGA-negative NSCLC and no history of tobacco use, the objective response rate (ORR) was 23.2%, median progression-free survival (mPFS) was 4.5 months, and median overall survival (mOS) was 16.8 months. PD-L1 ≥90% and tumor mutational burden (TMB) ≥90th percentile were independently and significantly associated with improved ORR, mPFS, and mOS (all P <0.01). PD-(L)1 + CTLA-4 combinations outperformed chemoimmunotherapy and PD-(L)1 monotherapy in terms of mPFS and mOS. Transcriptomic analysis revealed enrichment of innate and adaptive immune pathways in responders, including increased MHC class I/II antigen presentation and T-cell activity. High TIL density was also associated with superior ORR and PFS. Multiplexed immunophenotyping confirmed higher immune cell infiltration in patients who experienced durable clinical benefit. Conclusions: We demonstrated how combination therapies may improve ICI outcomes in patients with AGA-negative NSCLC and no history of tobacco exposure. Very high PD-L1, TMB, and immune-enriched phenotypes may guide treatment personalization.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Progression-free survival (left) and overall survival (right) according to co-mutation status for (A) CHEK2 and (B) ATRX in the overall mutation-evaluable population.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Progression-free survival (left) and overall survival (right) according to co-mutation status for (A) CHEK2 and (B) ATRX in the overall mutation-evaluable population.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Integrated model for patient stratification and clinical outcome prediction with KRAS G12Ci monotherapy in KRASG12C-mutant NSCLC.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Integrated model for patient stratification and clinical outcome prediction with KRAS G12Ci monotherapy in KRASG12C-mutant NSCLC.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
A) Venn diagram depicting co-mutation overlap between KEAP1, SMARCA4, and CDKN2A – KSC genes; survival outcomes according to co-mutation overlap in any of the KSC genes - PFS (B) and OS (C). Only patients whose tumor was profiled with a NGS panel providing coverage for all 3 genes were included in this analysis.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
A) Venn diagram depicting co-mutation overlap between KEAP1, SMARCA4, and CDKN2A – KSC genes; survival outcomes according to co-mutation overlap in any of the KSC genes - PFS (B) and OS (C). Only patients whose tumor was profiled with a NGS panel providing coverage for all 3 genes were included in this analysis.